| scholarly article | Q13442814 |
| P2093 | author name string | Kurt Van der Speeten | |
| Lieselotte Lemoine | |||
| Paul Sugarbaker | |||
| P2860 | cites work | Pharmacokinetic evaluation of intraperitoneal doxorubicin in rats | Q95567401 |
| A new standard of care for the management of peritoneal surface malignancy | Q24626790 | ||
| Fluorinated pyrimidines, a new class of tumour-inhibitory compounds | Q28214124 | ||
| Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. | Q33345134 | ||
| Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive su | Q33416659 | ||
| Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis | Q33418610 | ||
| For the clinical application of thermochemotherapy given at mild temperatures | Q33633382 | ||
| New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? | Q33992651 | ||
| Early postoperative intraperitoneal chemotherapy for macroscopically serosa-invading gastric cancer patients | Q34043376 | ||
| Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer | Q34055165 | ||
| Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone | Q34354500 | ||
| Experience with peritoneal mesothelioma at the Milan National Cancer Institute. | Q34391082 | ||
| Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials | Q34658004 | ||
| Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer | Q34996489 | ||
| Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis | Q35563273 | ||
| Intraperitoneal taxanes | Q35563289 | ||
| Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy | Q36021888 | ||
| Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy | Q36040207 | ||
| Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer | Q36151519 | ||
| Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: Pharmacologic studies | Q36452204 | ||
| Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside | Q36581822 | ||
| MUC2 protein expression status is useful in assessing the effects of hyperthermic intraperitoneal chemotherapy for peritoneal dissemination of colon cancer | Q36645647 | ||
| A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers | Q36989557 | ||
| Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix. | Q37145798 | ||
| XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center | Q37425429 | ||
| Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients | Q37662806 | ||
| Cell surface actions of adriamycin | Q37762978 | ||
| Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy | Q38047542 | ||
| Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States | Q38116391 | ||
| Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities | Q38183686 | ||
| Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference? | Q38728196 | ||
| What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures | Q38816501 | ||
| Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors. | Q39964992 | ||
| Pharmacokinetic study of perioperative intravenous Ifosfamide | Q40583827 | ||
| Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin | Q41614121 | ||
| Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. | Q41655647 | ||
| Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer | Q41673474 | ||
| Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes | Q42593114 | ||
| Pharmacology of perioperative 5‐Fluorouracil | Q42793414 | ||
| Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. | Q43064315 | ||
| Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients | Q43421690 | ||
| Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. | Q43703526 | ||
| Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial | Q43747422 | ||
| Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution | Q43910359 | ||
| 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer | Q43941230 | ||
| Importance of standardizing the dose in hyperthermic intraperitoneal chemotherapy (HIPEC): a pharmacodynamic point of view. | Q44242212 | ||
| Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex | Q44923750 | ||
| Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. | Q45341695 | ||
| Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). | Q45375023 | ||
| Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. | Q46647228 | ||
| HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy | Q46656530 | ||
| Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin. | Q46820137 | ||
| Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. | Q50512108 | ||
| Early postoperative intraperitoneal chemotherapy following cytoreductive surgery for appendiceal mucinous neoplasms with isolated peritoneal metastasis. | Q51352698 | ||
| Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. | Q52517952 | ||
| Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. | Q53081680 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. | Q53286355 | ||
| Temperature dependence studies of adriamycin uptake and cytotoxicity. | Q54402363 | ||
| Measurements of peritoneal surface area in man and rat | Q68142394 | ||
| Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies | Q68353048 | ||
| Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy | Q69609509 | ||
| The anticancer agent adriamycin can be actively cytotoxic without entering cells | Q70383981 | ||
| Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer | Q70424229 | ||
| In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C | Q70645905 | ||
| Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy | Q71636579 | ||
| Pharmacokinetics of mitomycin C (MMC) after intraperitoneal administration of MMC-gelatin gel and its anti-tumor effects against sarcoma-180 bearing mice | Q73383840 | ||
| Response to neo-adjuvant intraperitoneal and intravenous immunochemotherapy followed by interval secondary cytoreduction in stage IIIc ovarian cancer | Q73803847 | ||
| Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies | Q74305447 | ||
| Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer | Q79150738 | ||
| Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis | Q79345552 | ||
| Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: from laboratory bench to bedside | Q80343935 | ||
| Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis | Q80489973 | ||
| A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin | Q81698512 | ||
| Neoadjuvant treatment of gastric cancer with peritoneal dissemination | Q83169040 | ||
| Parietal peritonectomy | Q83418691 | ||
| Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy | Q83903423 | ||
| [Pharmacological bases of intraperitoneal chemotherapy] | Q84923826 | ||
| Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis | Q84966959 | ||
| Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis | Q85059510 | ||
| Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later? | Q87120214 | ||
| American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer | Q87417833 | ||
| The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery | Q87655048 | ||
| HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian c | Q88013132 | ||
| Phase I trial of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy in patients undergoing cytoreduction for advanced intra-abdominal malignancy | Q94679292 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 63-72 | |
| P577 | publication date | 2017-04-07 | |
| P1476 | title | Overview of the optimal perioperative intraperitoneal chemotherapy regimens used in current clinical practice | |
| P478 | volume | 2 |
Search more.